



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Private Bag X828, PRETORIA, 0001 Dr AB Xuma Building 1112 Voortrekker Road, Pretoria Townlands 351-JR,
PRETORIA, 0187 Tel (012) 395 8000, Fax (012) 395 8918

Mrs TL Burger
MC Pharma (Pty) Ltd
62 Constantia Avenue
Mnandi
Centurion
0157
Tshwane

Dear Mrs Burger

Section 21 Extension Authorization for THIOPENTONE 500MG INJECTION 20ML

Attached, please find the Authorization for exemption under Section 21 of the Medicines and Related Substances Act by SAHPRA granted for:

- **Thiopentone 500mg injection 20mL**

The quantities for which approval was granted are only estimates based on procurement by provinces over the last 6 months. Please note that the National Department of Health (NDOH) cannot guarantee the procurement of these quantities, as NDOH has no control over orders being placed by provincial depots, and current stock holding might influence estimated quantities.

The following process will be followed to ensure the quality of the product being brought in:

1. Manufacturer will submit an assay and identification of every batch imported.
2. An additional assay of every batch will be done by a quality control laboratory.
3. A random sample will be assayed during the authorized period by a quality control laboratory.
4. Aggregate statistics to be submitted to NDOH in the first week of each month of all orders received and quantities supplied per province.
5. The NDOH needs to be advised of the quantities and date of arrival of stocks in terms of this authorization within 7 days after arrival.
6. The supplier will provide monthly reports, by the 7th of each month, using the attached format of orders received and issues done.

Section 21 Extension Authorisation re Thiopentone 500mg INJ 26082025-1


7. Participating Authorities (PAs) will provide a consolidated close out report of usage using the attached format on the date when an authorization lapses.
8. The full quantities imported in terms of this Section 21 authorisation must be accounted for.
9. Note that this authorization DOES NOT cover supplies to the private sector.
10. Where this authorization is obtained to provide security of supply due to supply challenges from the contracted supplier, PAs are requested to buy out against contracted suppliers and ensure that related orders are cancelled accordingly to prevent overstocking once the contracted supplier gets back into stock.

It should be noted this authorization applies only for use of the product in the public sector with estimated usage quantities for a period of one month. The authorization is expected to expire on **14 February 2026**.

Table 1: Provincial usage

Province	Six Months Estimate	Actual Uptake
Correctional Services	0	0
EC-MT	300	130
EC-PE	100	
FS	120	0
GP	0	0
KZN	19	0
LP	1300	0
MP	0	0
NC	0	0
NW	0	0
SAMHS	0	0
WC	199	200
Total	2 038	330

Yours sincerely



KHADIJA JAMALOODIEN
CHIEF DIRECTOR: SECTOR WIDE PROCUREMENT
DATE: 27/8/2025

Section 21 Outcome Letter

2025-08-14

Ms Buhle Mbongo

National Department Of Health

Pretoria

buhle.mbongo@health.gov.za

Dear Ms Buhle Mbongo

REQUEST TO USE UNREGISTERED MEDICINE IN TERMS OF SECTION 21 OF THE MEDICINES AND CONTROLLED SUBSTANCES ACT, 1965 (ACT 101 of 1965):

Your application dated **2025-08-13** refers

- A. STATUS: Approved**
- B. APPLICANT: Ms Buhle Mbongo**
- C. IMPORTING COMPANY: MC PHARMA (PTY) LTD**
- D. NUMBER OF PATIENT/(S) INTENDED TO BE TREATED: 830**
- E. UNREGISTERED MEDICINES: GENERIC NAME: No Data**
- F. TRADE NAME: Thiosol 500 mg**
- G. QUANTITY: 1660 Packs (1)**

H. LETTER NUMBER: S2100009541

Section 21 authorization letters are valid for a period of 6 months from the letter date, unless otherwise specified.

A progress report must be submitted once treatment is completed or on a reauthorization request

Comments:

Yours faithfully,

Dr S Munbodh

Manager: Section 21 Category A Medicines



Mahlodi Maropa

Final Approver

S2100009541



SAHPRA Head Office
Building A, Loftus Park
2nd Floor
Kirkness Str
Arcadia
0083



MC Pharma (Pty) Ltd.
62 Constantia Avenue,
Mnandi, Centurion, 0157
Tel: +27 (0)12 668-3019
www.mcpharma.co.za



06 October 2024

QUOTATION # 20241007 T

TO: The National Department of Health

TEL: 012 395 0539

Email: Buhle.mbongo@health.gov.za

CONTACT PERSON / PATIENT: Buhle Mbongo

NB IMPORTED AND SUPPLIED UNDER SECTION 21 TERMS

PRODUCT CODE	DESCRIPTION	PACK SIZE	QUANTITY	PRICE EXCL	PRICE INCL
THIO 001	Each vial contains 500 mg Thiopentone Sodium BP.	1's	1	R68,66	R78,95
Brand		(packed in 1's)	1900	R130,454.00	R150,005.00
			Total	R130,454.00	R150,005.00

Valid for 90 days

Employee signature/s: _____

Date: 7 October 2024

Approved by: T Burger

MC Pharma (Pty) Ltd.
62 Constantia Avenue,
Mnandi, Centurion, 0157
Tel: +27 (0)12 668-3019
www.mcpharma.co.za



06 October 2024

TO: The National Department of Health

Directorate: Affordable Medicines

TEL: 012 395 0539

Email: Buhle.mbongo@health.gov.za

Dear Ms Mbongo

Re: RFQ S21RFQ139 – THIOPENTONE 500mg Injection

- | | |
|---|-----------------------------|
| • Quantity: | 1900 vials |
| • Delivery Time (weeks) | 8-12 weeks after approval |
| • Price (VAT inclusive) per vial | R78,95 per vial |
| • Generic Name: | Thiopentone Injection 500mg |
| • Trade/Brand Name: | THIOSOL Injection |
| • Packaging: | 1vial packed in 1's |
| • Specifications: | 500mg / Injection |
| • Shelf-life: | 24 months |
| • Package Insert: | Attached |
| • Manufacturer: | Neon Laboratories |
| • Country of Origin: | India |

Please note that the immediate availability of the product is under the condition that the manufacturer receives the notice of our order as soon as possible.

We are looking forward to your positive response and please do not hesitate to make contact should you have any further requirements.

Regards

pp

T Burger
Managing Director

during the induction procedure. For this reason it is not advised to use thiopental sodium alone for peroral endoscopy. Excessive doses are associated with hypothermia and profound cerebral impairment. An initial fall in blood pressure is often seen. Postoperative vomiting is infrequent, but shivering may occur and there may be persistent drowsiness, confusion and amnesia.

Other relatively common postoperative effects include anorexia, malaise, fatigue, and dizziness. Delirium has been noted in elderly patients. Allergic reactions, skin reactions and hypersensitivity have been rarely reported. Bronchospasm, respiratory depression and myocardial depression or cardiac arrhythmias may occur. Headache is also reported with the use of barbiturate anaesthetics.

DOSAGE AND ADMINISTRATION

Intravenous Injection:

Thiopental Sodium 500mg Injection is administered intravenously normally as a 2.5% w/v (500mg in 20ml) solution. On occasions it may be administered as a 5% w/v solution (500mg in 10ml). The intravenous injection preparation should be used after reconstitution of the sterile powder with Water for Injections, usually to produce a 2.5% w/v solution and this should be discarded after seven hours.

Use in anaesthesia:

Normal dosage for the induction of anaesthesia is 100mg to 150mg injected over 10 to 15 seconds. If necessary a repeat dose of 100mg to 150mg may be given after one minute. No fixed dosage recommendations for the intravenous injection can be given, since the dosage will need to be carefully adjusted according to the patient's response. Factors such as age, sex, and weight of the patient should be taken into consideration. Thiopental sodium reaches effective concentrations in the brain within 30 seconds and anaesthesia is normally produced within one minute of an intravenous dose.

Adult:

100mg to 150mg intravenously over 10 seconds to 15 seconds, normally as a 2.5% w/v solution. A repeat dose of 100mg to 150mg may be given after one minute. The intravenous injection should be given slowly and the amounts given titrated against the patient's response to minimize the risk of respiratory depression or the possibility of overdose. The average dose for an adult of 70kg is roughly 200mg to 300mg (8ml to 12ml of a 2.5% w/v solution) with a maximum of 500mg.

Children:

2 to 7mg/kg bodyweight, intravenously over 10 to 15 seconds, normally as a 2.5% w/v solution. A repeat dose of 2 to 7mg/kg may be given after one minute. The dose is 2 to 7mg/kg based on the patient's response. The dose for children should not exceed 7mg/kg.

Elderly:
Smaller adult doses are advisable.

Use in convulsive states:

75mg to 125mg (3ml to 5ml of a 2.5% w/v solution) should be given as soon as possible after the convulsion begins. Further doses may be required to control convulsions following the use of a local anaesthetic. Other regimens, such as the use of intravenous or rectal diazepam, may be used to control convulsive states.

Use in neurological patients with raised intracranial pressure:

Intermittent bolus injections of 1.5 to 3mg/kg of body weight may be given to reduce elevations of intracranial pressure if controlled ventilation is provided.

RECONSTITUTION OF SOLUTION

Thiosol (Thiopental Sodium for Injection B.P.) solutions should be prepared aseptically with the following diluents: Sterile Water for Injection USP. Reconstitute 500mg Thiosol with 20mL Sterile Water for Injection USP. Reconstitute 1g Thiosol with 20mL Sterile Water for Injection USP. Clinical concentrations used for intermittent intravenous administration vary between 2.0% w/v and 5.0% w/v. A 2.0% w/v or 2.5% w/v solution is most commonly used. A 3.4% w/v concentration in sterile water for injection is isotonic; concentrations less than 2.0% w/v in this diluent are not used because they cause hemolysis. For continuous intravenous drip administration, concentrations of 0.2% w/v or 0.4% w/v are used. Solutions may be prepared by adding Thiosol to 5% w/v Dextrose Injection USP, 0.9% w/v Sodium Chloride Injection USP.

Since Thiosol contains no added bacteriostatic agent, extreme care in preparation and handling should be exercised at all times to prevent the introduction of microbial contaminants. Solutions should be freshly prepared and used immediately after preparation. Sterilization by heating should not be attempted.

OVERDOSSAGE

Overdosage produces acute respiratory depression, hypotension, circulatory failure and apnoea. Treatment must be artificial ventilation, lowering of the patient's head and infusion of plasma volume expanders.

STORAGE

Store below 30°C., protected from light.

PRESENTATION

THIOSOL* (Thiopental Sodium for Injection B.P.) is available in a vial containing Thiopental Sodium E.P. 500mg/vial and 1g/vial.

MADE IN INDIA BY:

NEON LABORATORIES LTD.

28, Mahal Ind. Estate, M. Caves Road,
Andheri (East), Mumbai - 400 093.

P28A/9

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

THIOPENTAL SODIUM FOR INJECTION B.P. THIOSOL*

COMPOSITION

Each vial contains:


Thiopental Sodium B.P.

500 mg / 1g

DESCRIPTION

THIOSOL (Thiopental Sodium For Injection B.P.) is a thiobarbiturate, the sulfur analogue of sodium pentobarbital. It is available as a sterile powder and after reconstitution with an appropriate diluent is administered by the intravenous route. Thiosol is chemically designated sodium 5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate.

The structural formula is:



CLINICAL PHARMACOLOGY

Pharmacodynamic Properties :

Thiopental sodium is a short-acting substituted barbiturate that is more lipid soluble than other groups of barbiturates. The drug reversibly depresses the activity of all excitable tissues. The CNS is particularly sensitive and normally a general anaesthesia can be achieved with thiopental sodium without significant effects on peripheral tissues. Thiopental sodium acts through the CNS with particular activity in the mesencephalic reticular activating system. The barbiturates exert different effects on synaptic transmission, mostly those dependent on GABA. Autonomic ganglia of the peripheral nervous system are also depressed.

Pharmacokinetic Properties :

Following intravenous administration, unconsciousness occurs within 30 seconds and will be continued for 20 to 30 minutes after a single dose. Rapid uptake occurs to most vascular areas of the brain followed by redistribution into other tissues. Thiopental sodium is strongly bound to plasma protein, which impairs excretion through the kidney. The metabolites are usually inactive and are then excreted. Thiopental sodium, therefore, whilst having a short duration of action, may have a long elimination phase.

INDICATIONS AND USAGE

1. Thiopental sodium is used for the induction of general anaesthesia and is also used as an adjunct to provide hypnosis during balanced

<p>anaesthesia with other anaesthetic agents, including analgesics and muscle relaxants.</p> <p>2. Thiopental sodium is also used as an adjunct for control of convulsive disorders of various aetiology, including those caused by local anaesthetics.</p> <p>3. Thiopental sodium has now been used to reduce the intracranial pressure in patients with increased intracranial pressure, if controlled ventilation is provided.</p> <p>CONTRAINDICATIONS</p> <p>Thiopental sodium is contra-indicated in respiratory obstruction, acute asthma, severe shock and dystrophia myotonica. Administration of any barbiturate is contra-indicated in porphyria. Care should also be exercised with severe cardiovascular diseases, severe respiratory diseases and hypertension of various aetiology. Patients with hypersensitivity reactions to barbiturates.</p> <p>WARNINGS AND PRECAUTIONS</p> <p>Thiopental sodium causes respiratory depression and a reduction in cardiac output and may precipitate acute circulatory failure in patients with cardiovascular disease, particularly constrictive pericarditis.</p> <p>When particular caution is required :</p> <p>Special care is needed in administering thiopental sodium to patients with the following conditions:- hypovolaemia, severe haemorrhage, burns, cardiovascular disease, status asthmaticus, myaesthesia gravis, adrenocortical insufficiency (even when controlled by cortisone), cachexia, raised intracranial pressure and raised blood urea.</p> <p>Dose reduction required :</p> <p>Reduced doses are recommended in shock, dehydration, severe anaemia, hyperkalaemia, toxemia, metabolic disorders e.g., thyrotoxicosis, myxoedema and diabetes.</p> <p>Use in hepatic and renal disease :</p> <p>Thiopental sodium is metabolised primarily by the liver so doses should be reduced in patients with hepatic impairment. Barbiturate anaesthetics should be used with caution in severe renal disease. Reduced doses are also indicated in the elderly and in patients who have been premedicated with narcotic analgesics.</p> <p>Use with other medications and in underlying disease :</p> <p>Thiopental sodium has been shown to interact with sulphafurazole. Reduced initial doses may be required to achieve adequate anaesthesia, but repeat doses may also be necessary to maintain anaesthesia. Patients taking long-term medications such as aspirin, oral anticoagulants, oestrogens, MAOIs and lithium may need to adjust the dose or stop therapy prior to elective surgery. Patients with diabetes or hypertension may need to adjust their therapy before anaesthesia.</p> <p>Increased doses:</p> <p>Increased doses may be necessary in patients who have either a</p>		
---	--	--

<p>habituation or addiction to alcohol or drugs of abuse. Under these circumstances it is recommended that supplementary analgesic agents are used.</p> <p>Extravasation :</p> <p>Extravasation causes local tissue necrosis and severe pain. This can be relieved by application of an ice pack and local injection of hydrocortisone. The 5% w/v solution is hypertonic and may cause pain on injection and thrombophlebitis.</p> <p>Accidental intra-arterial injection :</p> <p>Accidental intra-arterial injection of thiopental sodium causes severe arterial spasm and an intense burning pain around the injection site. In the case of accidental intra-arterial injection of thiopental the needle should be left in-situ so that an injection of an antispasmodic, such as papaverine or pilocarpine hydrochloride may be given. Anticoagulant therapy may also be started to reduce the risk of thrombosis.</p> <p>Use during pregnancy and lactation :</p> <p>Thiopental sodium readily crosses the placental barrier and also appears in breast milk. Therefore, breast-feeding should be temporarily suspended or breast milk expressed before the induction of anaesthesia. It has been shown that thiopental sodium can be used without adverse effects during pregnancy although the total dose should not exceed 250mg. However, when considering use of thiopental sodium the clinician should only use the drug when the expected benefits outweigh any potential risks.</p> <p>Effects on ability to drive and use machines :</p> <p>Post-operative vertigo, disorientation and sedation may be prolonged and out-patients given thiopental sodium should therefore be advised not to drive or use machinery, especially within the first 24 to 36 hours.</p> <p>DRUG INTERACTIONS</p> <p>Thiopental sodium has been shown to interact with sulphafurazole. It should be noted that thiopental will interact with beta-blockers and calcium antagonists causing a fall in blood pressure.</p> <p>ACE inhibitors : enhanced hypotensive effect when general anaesthetics given with ACE inhibitors.</p> <p>Adrenergic neurone blockers: Enhanced hypotensive effect when general anaesthetics given with adrenergic neurone blockers.</p> <p>Alpha-blockers : Enhanced hypotensive effect when general anaesthetics given with alpha-blockers.</p> <p>Analgesics: Pretreatment with aspirin has been shown to potentiate thiopental sodium anaesthesia. Opioid analgesics can potentiate the respiratory depressant effect of barbiturate anaesthetics and the dose of anaesthetic may need to be reduced. The analgesic effect of</p>		
--	--	--

<p>pethidine can be reduced by thiopental sodium.</p> <p>Angiotensin-II receptor antagonists: Enhanced hypotensive effect when general anaesthetics given with angiotensin-II receptor antagonists.</p> <p>Antibacterials: General anaesthetics possibly potentiate hepatotoxicity of isoniazid; effects of thiopental sodium enhanced by sulphonamides; hypersensitivity-like reactions can occur when general anaesthetics given with intravenous vancomycin.</p> <p>Antidepressants: Increased risk of arrhythmias and hypotension when general anaesthetics given with tricyclic antidepressants. Hypotension and hypertension has been seen with MAOIs.</p> <p>Antipsychotics: Patients being treated with phenothiazine antipsychotics may experience increased hypotension. Some phenothiazines, especially promethazine, may also increase the incidence of excitatory phenomena produced by barbiturate anaesthetics; cyclizine may possibly have a similar effect. The sedative properties may be also potentiated by thiopental sodium.</p> <p>Benzodiazepines: Midazolam potentiates the anaesthetic effects of thiopental sodium.</p> <p>Diazoxide: Enhanced hypotensive effect when general anaesthetics given with diazoxide.</p> <p>Diuretics: Enhanced hypotensive effect when general anaesthetics given with diuretics.</p> <p>Gastrointestinal drugs: Metoclopramide and droperidol reduce the dose of thiopental sodium required to induce anaesthesia.</p> <p>Methyldopa: enhanced hypotensive effect when general anaesthetics given with methyldopa.</p> <p>Moxonidine: Enhanced hypotensive effect when general anaesthetics given with moxonidine</p> <p>Nitrates: Enhanced hypotensive effect when general anaesthetics given with nitrates.</p> <p>Probenecid: Pretreatment with probenecid has been shown to potentiate thiopental sodium anaesthesia.</p> <p>Vasodilator antihypertensives: Enhanced hypotensive effect when general anaesthetics given with hydralazine, minoxidil or nitroprusside.</p> <p>The use of anaesthetics with other CNS depressant drugs such as those used for premedication may produce synergistic effects on the CNS and, in some cases; a smaller dose of general anaesthetic should be used. Bradycardia occurring during anaesthetic induction with thiopental has been reported in patients also receiving fentanyl.</p> <p>ADVERSE REACTIONS</p> <p>Laryngeal spasm may occur, together with coughing or sneezing.</p>		
---	--	--



Artwork of Carton

Design 100%

Actual Dimensions 38 (L) x 38 (B) x 67 (H) mm



PANTONE 688 C



BLACK